Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that TriSalus Life Sciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: TLSI reported Q1 2026 revenue of $8.9 million. Wall Street consensus had projected $9.4 million -- a shortfall of approximately $500,000, or more than 5%. The miss arrived approximately two months after CEO Mary Szela reaffirmed full-year 2026 revenue guidance of $60 million to $62 million on the Q4 2025 earnings call on March 5, 2026. Alongside the Q1 miss, the company cut its full-year 2026 revenue outlook to $54 million to $57 million -- a reduction of up to $8 million from the range reaffirmed in March 2026. The revised midpoint of $55.5 million represented a roughly 9% reduction from the prior midpoint of $61 million.
In order to be eligible to join the TLSI class action lawsuit, you must have incurred a loss on shares of TriSalus Life Sciences, Inc. purchased during the class period listed above.
TOP
